Survival and stability of patients with urothelial cancer and spinal bone metastases after palliative radiotherapy
, , , , , , , and | Sep 14, 2017
About this article
Article Category: Research Article
Published Online: Sep 14, 2017
Page range: 189 - 194
Received: Jun 09, 2017
Accepted: Aug 14, 2017
DOI: https://doi.org/10.1515/raon-2017-0038
© 2017 Robert Foerster, Katharina Hees, Thomas Bruckner, Tilman Bostel, Ingmar Schlampp, Tanja Sprave, Nils H. Nicolay, Juergen Debus, Harald Rief, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Patients’ characteristics of all patients with urothelial cancer and spinal bone metastases
| Patients’ characteristics | ||
|---|---|---|
| Median | 70 years | |
| Range | 35-82 years | |
| % | ||
| Female | 8 | 21.0% |
| Male | 30 | 79.0% |
| 40-60% | 12 | 31.6% |
| 70% | 17 | 44.7% |
| 80% | 9 | 23.7% |
| Urothelial carcinoma | 38 | 100% |
| Thoracic | 18 | 47.4% |
| Lumbar | 20 | 52.6% |
| Single | 15 | 39.5% |
| Multiple | 23 | 60.5% |
| Overall | 9 | 23.7% |
| Lungs | 6 | 15.8% |
| Liver | 5 | 13.2% |
| Brain | 2 | 5.3% |
| Yes | 6 | 15.8% |
| No | 32 | 84.2% |
| Instability | 7 | 18.4% |
| Neurological symptoms | 1 | 2.6% |
| Pain | 30 | 79.0% |
| 10 x 3 Gy | 24 | 63.2% |
| 14 x 2.5 Gy | 3 | 7.9% |
| 20 x 2 Gy | 11 | 28.9% |
| Chemotherapy | 14 | 36.8% |
| Bisphosphonates | 4 | 10.5% |